Merck and Moderna say cancer vaccine shows promise in preventing recurrence of melanoma - NBC News

“A Phase III trial of an experimental mRNA vaccine co‑developed by Merck and Moderna demonstrated a significant reduction in melanoma recurrence, suggesting a potential new standard of care for patients after surgical removal of the tumor. The vaccine leverages the same mRNA platform that powered COVID‑19 shots, allowing rapid scaling through existing U.S. manufacturing capacity and potentially accelerating FDA review. If approved, the therapy could address a $1.5 billion U.S. market for advanced skin‑cancer treatments and may be incorporated into insurance formularies, expanding access for American patients. Expert Analysis: This breakthrough could shift oncology practice from reactive therapies to preventive immunization, giving Merck and Moderna a lucrative foothold in the U.S. cancer‑vaccine space. Early adoption may also pressure competitors to accelerate their own mRNA‑based oncology pipelines, intensifying market competition over the next few years.”